News

The FDA has granted a priority review designation to pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

The FDA has granted a priority review designation to a supplemental Biologics License Application (sBLA) for durvalumab (Imfinzi) for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1

Here are the top 5 Oncology Nursing News® stories for November 2019.

JAK inhibitors have been the standard of care for patients with myelofibrosis, but now patients need novel agents to help.

The FDA has granted a priority review to the agent pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

New approvals in the treatment of patients with myeloma has led to the question of what sequencing of drugs will work best for patients.

Two new single agents led to brain penetrance and 2-hydroxyglutarate (2-HG) suppression in patients with low-grade glioma who harbor IDH1 mutations, according to updated findings.

New real-world data shows that PARP inhibitors have the potential to help patients with ovarian cancer and could be an affordable option for them.

Canada’s first immunotherapy oncology program provides patient education to not only help them understand the therapy but also mitigate immune-related adverse events.

Drug prices for cancer care are rising considerably, but biosimilars are poised to help patients with cancer handle these prices. Particularly, patients with breast cancer.

In this month’s episode of the "CURE Talks Cancer Podcast: Nursing Edition," we had the chance to talk with Betty Ferrell, FAACN, FCPN, MA, PhD, director of the Division of Nursing Research and Education at City of Hope, and discuss the important differences between palliative care and end of life care.

The FDA has approved acalabrutinib for the treatment of adult patients with CLL or SLL.

In a phase III trial of nivolumab/ipilimumab to treat patients with melanoma in the adjuvant setting results showed the drugs missed their coprimary end point.

New studies are showing the dawn of a new era in how cancer care teams will go about treating patients with small cell lung cancer with immunotherapy combinations.

The FDA accepts the application of a biosimilar of bevacizumab in the treatment of patients with NSCLC.

Immunotherapy as a frontline treatment for patients with advanced nonsquamous NSCLC is showing potential, but there is still additional testing that needs to be done.

Biosimilars are beginning to change the way oncology professionals treat patients with cancer, and this could help alleviate the financial burden of care.

Patients with cancer undergoing stem cell transplant are experiencing depression at higher rates than other cancer survivors, and special interventions are required to address their psychosocial needs.

The Food and Drug Administration granted accelerated approval to zanubrutinib for the treatment of relapsed and refractory mantle cell lymphoma.

Lung cancer treatments are advancing. With these changes come new complications and questions that nurses will have to address with their patients.

Multiple CDK4/6 inhibitors have shown impressive OS survival benefit in multiples studies of patients with metastatic HR+ breast cancer.

The FDA has granted a priority review to the combination treatment of nivolumab and ipilimumab to treat patients with advanced HCC.

The therapy is now approved for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

With the help of NGS, new research is emerging for targeted therapies of rare mutations in lung cancer.

Precision medicine is sweeping across the cancer care spectrum, and now, experts have their sights set on applying it in MCL.

Steps in orthopedic oncology are being made after the first-ever global perspective trial in its field completed patient accrual.

Several late-stage therapies, including targeted agents and immunotherapies, are being evaluated for patients with relapsed/refractory colorectal cancer (CRC) who have progressed on first- and second-line therapies.

New study results show that chemoimmunotherapy combination options provide an overall survival benefit to patients with stage IV nonsquamous NSCLC.

The FDA has approved the biosimilar pegfilgrastim for treatment to decrease the incidence of infection exhibited from febrile neutropenia.

Wnt emerges as an exciting and favorable pathway for the treatment of patients with CRC.